ROCO
8279
Market cap74mUSD
Jul 09, Last price
88.00TWD
1D
0.00%
1Q
-17.37%
Jan 2017
-3.65%
IPO
165.94%
Name
Syngen Biotech Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in 1988 and based in Tainan City, Taiwan, Syngen Biotech Co.,Ltd. operates globally, including in Taiwan and China, specializing in the research, development, production, and sale of a diverse array of products. Its core offerings include microbial pharmaceutical raw materials, biological pesticides, fertilizers, biochemical nutritional products, and preventive medicines. The company further manufactures dietary supplements and provides comprehensive contract manufacturing services for supplements, accommodating various formats such as sachets, liquids, tablets, cup package capsules, jellies, aluminum and glass bottles, and gummies. Syngen Biotech also develops and markets science-backed bioactive pharmaceutical ingredients (APIs) under proprietary brands including Oraltics, IMMUPHYLA, V3, ST4SanTex, GUARDSPO, benefiGANO, EXPUNERGY, and BIOJOVIAL. Additional services encompass private labelling, organic food OEM/ODM, explosion-proof extraction, brand agency, and wholesale distribution. Syngen Biotech caters to numerous industries, such as sport nutrition, beauty enhancement, baby and mother care, weight management, and digestion and detox. The company actively exports its products to approximately 20 countries worldwide.
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||